CTX-009 (DLL4 X VEGF-A bispecific) - (COMPANION-002)

July 17, 2026: Compass Therapeutics, Inc. (NASDAQ: CMPX) announced that its abstract, “A randomized trial of paclitaxel ± tovecimig in previously treated patients with advanced biliary tract cancer,” has been accepted for an oral Proffered Paper presentation at the European Society for Medical Oncology (ESMO) Congress (Oct. 23–27, 2026; Madrid, Spain). The presentation will highlight results from the randomized, controlled Phase 2/3 COMPANION-002 trial evaluating tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel in patients with advanced biliary tract cancer. The talk will be presented by Dr. Nilofer Azad (Johns Hopkins) on Saturday, Oct. 24, 2026, during the 10:15–11:45am CET session. Additional presentation details will be released per ESMO policies.